DV
Dividend Vision

NRXP — NRX Pharmaceuticals Inc

NRX Pharmaceuticals Inc (NRXP)

Total return is -96.6% over the past 8.7 years, 333.1 points behind SPY at 236.5%. Its deepest 1-year drawdown was 54.2%.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders including suicidal depression, PTSD, and schizophrenia, with lead candidates NRX-101 and NRX-100 in clinical testing; it also operates an interventional psychiatry services business offering ketamine infusion therapy, transcranial magnetic stimulation, and related treatments. The company does not currently distribute dividends. NRx Pharmaceuticals appeals to investors seeking exposure to early-stage pharmaceutical development rather than current income.

NRXP key facts

Asset type
Stock
Asset class
Equity
Inception date
12/04/2017
Last close
$3.27
Market cap
$178,905,744
Average volume
1128895.0
Beta
2.191
Payout ratio
0.0
Forward P/E
34.2466
EPS
$-1.02